Clinical trials: Neoplasms, Solid Tumor
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
This is an open-label, randomized, multi-center phase II study to evaluate the safety, tolerability, PK, and efficacy of SHR-4602 monotherapy in subjects with HER2-expressing or -mutated unresectable or metastatic solid tumors.
- Trial name
- NCT06516926
- Testing
- SHR-4602
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
Advanced Solid Tumors
A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors
Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors.
- Trial name
- NCT07767474
- Testing
- ATX-898, ATX-898, fulvestrant, ribociclib
- Where
- 6 sites in United States, Australia
- Volunteers
- 343 people
- Sponsor
- Antares Therapeutics, Inc
Tumors
One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy
This study will include a one time intravenous (IV) infusion of Clostridium novyi-NT (C. novyi-NT) spores to treat solid tumors which have not responded to standard therapy.
- Trial name
- NCT00358397
- Testing
- Clostridium novyi-NT spores
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor
Irinotecan in Treating Children With Refractory Solid Tumors
This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma
- Trial name
- NCT00004078
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Children's Oncology Group
Gastrointestinal Tumors
Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors
This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic…
- Trial name
- NCT05981235
- Testing
- AZD6422 CLDN18.2 CAR-T product
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Peking University
Solid Tumor
HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors
This Phase1, open-label and dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX07 administered as a single-agent by IV infusion every 3 weeks to patients with…
- Trial name
- NCT05360368
- Testing
- HLX07
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Henlius Biotech
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer
- Trial name
- NCT00003926
- Testing
- amifostine trihydrate, busulfan, filgrastim
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Unspecified Adult Solid Tumor, Protocol Specific
CP-609,754 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CP-609,754 in treating patients who have advanced solid…
- Trial name
- NCT00006085
- Testing
- CP-609,754
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Tumor of Digestive Tract or Urinary System
A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors
This is an open-lable, single-arm, dose escalation and dose extension phase I clinical study of ScTIL designed to observe and evaluate the safety, the tolerance, the pharmacokinetic characteristics and the effectiveness of ScTIL…
- Trial name
- NCT05499715
- Testing
- ScTIL injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chinese Academy of Medical Sciences
Advanced Solid Tumor
A Study of MSB0254 Injection in Advanced Solid Tumors
This study was an open, multi-dose dose escalation phase I clinical study to evaluate the safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or metastatic solid tumors, and to preliminarily…
- Trial name
- NCT04381325
- Testing
- MSB0254 Injection
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Advanced Solid Tumor, NSCLC
A Study of XZB-0004 in Patients With Solid Tumors
XZB-0004 is a novel and potent small molecule inhibitor of receptor tyrosine kinase AXL. This is an open-label, multicentre phase I study of XZB-0004 in patients with solid tumors.
- Trial name
- NCT05772455
- Testing
- XZB-0004
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiosurgery in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving stereotactic radiosurgery before surgery may make the tumor smaller and reduce the amount of…
- Trial name
- NCT00811655
- Testing
- therapeutic conventional surgery, stereotactic radiosurgery
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Metastatic Solid Tumors
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study
This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.
- Trial name
- NTRK (NCT04010240)
- Testing
- No intervention (this is a retrospective cohort study)
- Where
- France
- Volunteers
- 3,820 people
- Sponsor
- Institut Bergonié
Pre-malignant, Malignant
Prospective Evaluation of Diagnostic Performance of PanTum Detect Test in Adult Patients With Suspected or Confirmed Macroscopic Solid Pre-malignant or Malignant Lesion(s) Referred to Fludeoxyglucose (18F) PET/CT and in Adult Healthy Population
This prospective phase II trial aims to evaluate the diagnostic performance of multi-cancer epitope diagnosis in monocyte (EDIM) based blood test PanTum detect test for early detection of individuals with pre-malignant or…
- Trial name
- PanTumPET (NCT06842615)
- Testing
- Pantum detect test
- Where
- Slovakia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Comenius University
Advanced Solid Tumor
Clinical Study of CVL006 Injection in Advanced Solid Tumors
Evaluate the safety and tolerability of CVL006 monotherapy in patients with advanced solid tumors; Observe the dose limiting toxicity (DLT) of CVL006 monotherapy in patients with advanced solid tumors, evaluate the maximum…
- Trial name
- NCT06621615
- Testing
- CVL006 Injection
- Volunteers
- 120 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Refractory Solid Tumors, Pancreatic Adenocarcinoma
A Phase I/Expansion Study of Dasatinib
The purpose of this study is to find the highest dose of the drugs gemcitabine and dasatinib that can be given for the treatment of pancreatic cancer. Gemcitabine (also called Gemzar™)is a drug that is given intravenously.
- Trial name
- Gem/Dsat (NCT00598091)
- Testing
- gemcitabine, dasatinib
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Solid Tumor Cancer, Neoplasms
AI-Driven Tumor Response Evaluation for Solid Tumors
Purpose: This study is developing and validating an artificial intelligence (AI)-driven system to evaluate tumor response using changes in total tumor volume.
- Conditions
- Solid Tumor Cancer, Neoplasms, Hepatocellular Carcinoma
- Trial name
- NCT07685548
- Testing
- Observational Data Collection
- Volunteers
- 6,120 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell…
- Trial name
- NCT07724535
- Testing
- 18F-grazy-02
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking University Cancer Hospital & Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.